Stockscreener 앱 받기
0.3527
7.16%
-0.0272
Bioatla Inc 주식(BCAB)의 최신 뉴스
BioAtla Inc. stock trend outlook and recovery pathFree Stable Entry High Return Opportunities - Newser
Using data filters to optimize entry into BioAtla Inc.Entry Optimization Tool with Screener Logic - Newser
What institutional flow reveals about BioAtla Inc.Automated AI Forecast with Trading Alerts - Newser
Does BioAtla Inc. stock have upside surprise potentialDaily Breakout Recap Watch - sisaissue.com
What technical models suggest about BioAtla Inc.’s comebackFree Alpha Driven Watchlist With Alerts - Newser
BioAtla, Inc. Reports Q2 2025 Financial Results and Clinical Progress - TipRanks
Head-To-Head Review: Alzamend Neuro (NASDAQ:ALZN) & BioAtla (NASDAQ:BCAB) - Defense World
Sector ETF performance correlation with BioAtla Inc.Free Alpha Driven Watchlist With Alerts - Newser
Comparing BioAtla Inc. in custom built stock radarsFree Swing Setup With Technical Confirmation - Newser
BioAtla's Strategic Position in Immuno-Oncology and Partnership-Driven Growth - AInvest
Why BioAtla Inc. stock attracts strong analyst attentionSwing Trade Signal and Price Prediction - Newser
BioAtla August 2025 slides: promising clinical data amid financial headwinds By Investing.com - Investing.com Nigeria
Earnings call transcript: Bioatla Q2 2025 misses EPS forecasts By Investing.com - Investing.com South Africa
Earnings call transcript: Bioatla Q2 2025 misses EPS forecasts - Investing.com
BioAtla August 2025 slides: promising clinical data amid financial headwinds - Investing.com
BioAtla Inc Reports Q2 2025 EPS of -$0.32, Missing Estimates; Net Loss at $18.7 Million - AInvest
BioAtla faces Nasdaq delisting over share price rule - MSN
BioAtla Inc (BCAB) Q2 2025 Earnings Call Highlights: Promising Clinical Progress Amid Financial ... By GuruFocus - Investing.com Canada
Bioatla Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Transcript : BioAtla, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
BioAtla, Inc. SEC 10-Q Report - TradingView
BioAtla Reports Second Quarter 2025 Financial Results and Highlights Recent Progress - The Manila Times
BioAtla's Cancer Treatment Achieves 45% Response Rate, FDA Meeting Set for Q3 2025 - Stock Titan
BioAtla Q2 FY23: $ revenue, financial results, conference call August 7, 2025. - AInvest
Top Risks to Consider Before Buying BioAtla Inc. StockBreakout Watcher with Entry and Exit Alerts - Newser
Automated trading signals detected on BioAtla Inc.High Accuracy Trade Setup Identification - Newser
What makes BioAtla Inc. stock price move sharplyDaily Technical Chart Pattern Analysis Report - Newser
BioAtla to Announce Second Quarter 2025 Financial Results and Provide Business Highlights on August 7, 2025 - The Manila Times
Clinical-Stage Biotech BioAtla Sets Q2 Earnings Date: Key Updates on CAB Cancer Therapeutics Expected - Stock Titan
Is BioAtla Inc. stock overvalued or undervaluedMarket-beating performance - Jammu Links News
How many analysts rate BioAtla Inc. as a “Buy”Achieve breakthrough performance with smart picks - Jammu Links News
How volatile is BioAtla Inc. stock compared to the marketTurn volatility into profit opportunities - Jammu Links News
What is the risk reward ratio of investing in BioAtla Inc. stockExplosive capital appreciation - Jammu Links News
Is it the right time to buy BioAtla Inc. stockUnlock exclusive trading strategies for gains - Jammu Links News
Should I hold or sell BioAtla Inc. stock in 2025Massive wealth growth - Jammu Links News
0.24%
3.39%
자본화:
|
볼륨(24시간):